Key result
Ticagrelor linked to reversible Cheyne-Stokes respiration and central sleep apnea.
Why the study?
Cheyne-Stokes respiration with central sleep apnea was reported in patients after initiation of ticagrelor therapy, suggesting a potential adverse effect.
Does ticagrelor cause Cheyne-Stokes respiration with central sleep apnea?
Does ticagrelor cause Cheyne-Stokes respiration with central sleep apnea?
This case series highlights a potential novel adverse effect of ticagrelor, indicating it may induce reversible Cheyne-Stokes respiration and central sleep apnea.
Ticagrelor is a P2Y12 receptor antagonist used in first-line dual-antiplatelet therapy in coronary artery disease [(1)][1]. Cheyne-Stokes respiration with central sleep apnea was reported in 4 patients after ticagrelor therapy was initiated and disappeared after ticagrelor withdrawal and switch to
No takes yet. Share an insight, caveat, or question.
Revol et al. (2018) studied this question. Ticagrelor therapy was associated with Cheyne-Stokes respiration and central sleep apnea in 4 patients, which disappeared after drug withdrawal.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: